Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Net Margin (2016 - 2026)

Standard Biotools has reported Net Margin over the past 16 years, most recently at 9.12% for Q4 2025.

  • Quarterly Net Margin fell 6511.0% to 9.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 76.07% through Dec 2025, down 1457.0% year-over-year, with the annual reading at 87.77% for FY2025, 6271.0% up from the prior year.
  • Net Margin was 9.12% for Q4 2025 at Standard Biotools, up from 177.41% in the prior quarter.
  • Over five years, Net Margin peaked at 73.36% in Q4 2023 and troughed at 338.46% in Q2 2022.
  • The 5-year median for Net Margin is 70.61% (2024), against an average of 90.08%.
  • Year-over-year, Net Margin surged 45809bps in 2021 and then tumbled -28319bps in 2022.
  • A 5-year view of Net Margin shows it stood at 48.64% in 2021, then plummeted by -84bps to 89.44% in 2022, then surged by 182bps to 73.36% in 2023, then dropped by -24bps to 56.0% in 2024, then plummeted by -116bps to 9.12% in 2025.
  • Per Business Quant, the three most recent readings for LAB's Net Margin are 9.12% (Q4 2025), 177.41% (Q3 2025), and 81.21% (Q2 2025).